	US 12,252,720 B2
	Alpha-amylase variants and polynucleotides encoding same
Carsten Andersen, Vaerloese (DK); Randall Deinhammer, Wake Forest, NC (US); Thomas Agersten Poulsen, Ballerup (DK); Miguel Duarte Toscano, Frederiksberg (DK); Peter Kamp Hansen, Lejre (DK); Henrik Friis-Madsen, Ballerup (DK); Anders Viksoe-Nielsen, Slangerup (DK); Signe Eskildsen Larsen, Lyngby (DK); and Lars L. H. Christensen, Alleroed (DK)
Assigned to Novozymes A/S, Bagsvaerd (DK); and Novozymes North America, Inc., Franklinton, NC (US)
Filed by Novozymes A/S, Bagsvaerd (DK); and Novozymes North America, Inc., Franklinton, NC (US)
Filed on Feb. 6, 2023, as Appl. No. 18/165,023.
Application 18/165,023 is a division of application No. 16/715,041, filed on Dec. 16, 2019, granted, now 11,603,522.
Application 16/715,041 is a division of application No. 15/137,852, filed on Apr. 25, 2016, granted, now 10,550,373, issued on Feb. 4, 2020.
Application 15/137,852 is a division of application No. 13/515,437, granted, now 9,416,355, issued on Aug. 16, 2016, previously published as PCT/US2011/020128, filed on Jan. 4, 2011.
Claims priority of provisional application 61/292,324, filed on Jan. 5, 2010.
Claims priority of provisional application 61/292,327, filed on Jan. 5, 2010.
Claims priority of provisional application 61/304,092, filed on Feb. 12, 2010.
Claims priority of provisional application 61/333,930, filed on May 12, 2010.
Claims priority of provisional application 61/354,775, filed on Jun. 15, 2010.
Claims priority of provisional application 61/354,817, filed on Jun. 15, 2010.
Claims priority of provisional application 61/355,230, filed on Jun. 16, 2010.
Claims priority of provisional application 61/362,536, filed on Jul. 8, 2010.
Claims priority of application No. 10150062 (EP), filed on Jan. 4, 2010; and application No. 10150063 (EP), filed on Jan. 4, 2010.
Prior Publication US 2023/0183666 A1, Jun. 15, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 9/28 (2006.01); C11D 3/386 (2006.01); C12N 9/26 (2006.01); C12N 15/82 (2006.01); C12P 7/06 (2006.01); C12P 7/14 (2006.01); C12P 19/02 (2006.01); C12P 19/04 (2006.01); C12P 19/14 (2006.01)

CPC C12N 9/2417 (2013.01) [C11D 3/386 (2013.01); C11D 3/38681 (2013.01); C12N 9/2414 (2013.01); C12N 15/8257 (2013.01); C12P 7/06 (2013.01); C12P 7/14 (2013.01); C12P 19/02 (2013.01); C12P 19/04 (2013.01); C12P 19/14 (2013.01); C12Y 302/01001 (2013.01); C12P 2203/00 (2013.01); Y02E 50/10 (2013.01)]

32 Claims

1. A variant alpha-amylase, comprising an amino acid sequence having at least 90% and less than 100% sequence identity to the mature polypeptide of the amino acid sequence of SEQ ID NO: 1, 2, 3, 4, 5, 6, and/or 7, wherein said variant comprises a set of substitutions at positions corresponding to positions 129, 177 and 179 of the amino acid sequence of SEQ ID NO: 1 and further comprises a substitution at three or more positions corresponding to positions 59, 89, 91, 96, 108, 112, 157, 165, 166, 168, 171, 180, 181, 184, 208, 220, 224, 242, 254, 269, 270, 274, 276, 281, 284, 416, and 427 of the amino acid sequence of SEQ ID NO: 1, wherein the variant has alpha-amylase activity.